Optimal Prandial Timing of Insulin Bolus in Youths with Type 1 Diabetes: A Systematic Review

Author:

Mozzillo Enza,Franceschi RobertoORCID,Di Candia Francesca,Ricci Alessia,Leonardi Letizia,Girardi Martina,Rosanio Francesco Maria,Marcovecchio Maria LoredanaORCID

Abstract

The aim of this systematic review was to report the evidence on optimal prandial timing of insulin bolus in youths with type 1 diabetes. A systematic search was performed including studies published in the last 20 years (2002–2022). A PICOS framework was used in the selection process and evidence was assessed using the GRADE system. Up to one third of children and adolescents with type 1 diabetes injected rapid-acting insulin analogues after a meal. Moderate–high level quality studies showed that a pre-meal bolus compared with a bolus given at the start or after the meal was associated with a lower peak blood glucose after one to two hours, particularly after breakfast, as well as with reduced HbA1c, without any difference in the frequency of hypoglycemia. There were no differences related to the timing of bolus in total daily insulin and BMI, although these results were based on a single study. Data on individuals’ treatment satisfaction were limited but did not show any effect of timing of bolus on quality of life. In addition, post-prandial administration of fast-acting analogues was superior to rapid-acting analogues on post-prandial glycemia. There was no evidence for any difference in outcomes related to the timing of insulin bolus across age groups in the two studies. In conclusion, prandial insulin injected before a meal, particularly at breakfast, provides better post-prandial glycemia and HbA1c without increasing the risk of hypoglycemia, and without affecting total daily insulin dose and BMI. For young children who often have variable eating behaviors, fast-acting analogues administered at mealtime or post-meal could provide an additional advantage.

Publisher

MDPI AG

Subject

Medicine (miscellaneous)

Reference29 articles.

1. ISPAD Clinical Practice Consensus Guidelines 2018, Glycemic control targets and glucose monitoring for children, adolescents, and young adults with diabetes;DiMeglio;Pediatr. Diabetes,2018

2. Novo Nordisk A/S (2022, October 22). NovoRapid Summary of Product Characteristics. Available online: www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000258/WC500030372.pdf.

3. Eli Lilly (2022, October 22). Humalog Summary of Product Characteristics. Available online: www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000088/WC500050332.pdf.

4. Sanofi-Aventis (2022, October 22). Apidra Summary of Product Characteristics. Available online: www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000557/WC500025250.pdf.

5. The pharmacokinetics and pharmacodynamics of rapid-acting insulin analogues and their clinical consequences;Home;Diabetes Obes. Metab.,2012

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3